Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy

Authors:

Top Cited Papers
Open Access
Abstract
Epilepsy affects 50 million people worldwide.1 The treatment goal for newly diagnosed epilepsy is seizure freedom, usually defined as no seizures for 12 months or more,2 achieved as soon as possible with minimal or no treatment-related adverse effects. This goal is achieved using antiseizure medications (ASMs), which suppress the occurrence of seizures without modifying the underlying pathology.3 Choosing the first ASM is of paramount importance because an inadequate response to the first prescribed drug is a strong predictor of poor subsequent long-term outcome.4-6 A proportion of patients whose first ASM treatment fails will respond to subsequent treatments,6 which implies that they might have become seizure free sooner if they were given the “right drug” at the outset.

This publication has 53 references indexed in Scilit: